CEVEC Signs Global License Agreement for Human CAP-T Technology with Life Technologies

19-Aug-2010 - Germany

CEVEC Pharmaceuticals announced the signing of a co-exclusive worldwide licensing agreement with Life Technologies Corporation. Under the terms of the agreement, Life Technologies and CEVEC will co-operate to offer optimized Expression kits based on CEVEC’s proprietary CAP-T cells to the global life science research community. Life Technologies will pay CEVEC a signing fee and various milestone payments and royalties on sales of the future products. Further details of the agreement were not disclosed. CEVEC will continue to expand its global license business of the CAP® and CAP-T® technologies for commercial use and industrial development purposes.

CEVEC’s transient CAP-T protein production technology is based on CAP cells, a human immortalized cell line for stable protein production derived from amniocytes. CAP cells are optimized to growth in serum-free suspension cultures and show human-like post-translational modifications including authentic human glycosylation patterns.

Life Technologies combines CEVEC’s proprietary protein expression system based on CAP cells with its tailored protein expression product portfolio (media, transfection reagents etc.) to enable research scientists worldwide to achieve highest yield and quality protein expression.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances